A Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Subjects With Active Psoriatic Arthritis
Study Purpose
This study is designed to evaluate the efficacy, safety, and tolerability of NDI-034858 in subjects with active Psoriatic Arthritis (PsA).
Recruitment Criteria
Accepts Healthy Volunteers
Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms |
No |
Study Type
An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes. Searching Both is inclusive of interventional and observational studies. |
Interventional |
Eligible Ages | 18 Years - 70 Years |
Gender | All |
Inclusion Criteria:
- - Subject has PsA on the basis of the Classification Criteria for Psoriatic Arthritis with peripheral symptoms at the screening visit.
- - Subject has a history of PsA symptoms for ≥ 6 months prior to the screening visit.
- - Subject has ≥ 3 tender joints and ≥ 3 swollen joints at screening and Day 1 visits.
- - Subject has at least one lesion of plaque psoriasis ≥ 2 cm in diameter, nail changes characteristic of psoriasis, or a documented history of plaque psoriasis.
- - Subject has active PsA despite previous standard doses of non-steroidal anti-inflammatory drug (NSAIDs) administered for ≥ 4 weeks, or traditional disease-modifying anti-rheumatic drug (DMARDs) (including methotrexate and sulfasalazine) administered for ≥ 3 months, or tumor necrosis factor inhibitor (TNFi) agents administered for ≥ 3 months, or subjects are intolerant to NSAIDs or DMARDs or TNFi agents.
- - If subject is on concurrent PsA treatments, they must be on stable doses.
- - All female subjects should followed the protocol defined contraceptive method.
Exclusion Criteria:
- - Subject has other disease(s) that might confound the evaluations of benefit of NDI-034858 therapy, including but not limited to rheumatoid arthritis (RA), axial spondyloarthritis (this does not include a primary diagnosis of PsA with spondylitis), systemic lupus erythematosus, Lyme disease, or fibromyalgia.
- - Subject has a history of lack of response to any therapeutic agent targeting IL-12, IL17, and/or IL23 at approved doses after at least 12 weeks of therapy, and/or received one of these therapies within 6 months prior to baseline (Day 1).
- - Subject has a history of lack of response to > 1 therapeutic agent targeting tumor necrosis factor.
- - Subject has received infliximab, golimumab, adalimumab, or certolizumab pegol, or any biosimilar of these agents, within 8 weeks prior to baseline (Day 1).
- - Subject has received etanercept, or any biosimilar of etanercept, within 4 weeks prior to baseline (Day 1).
- - Subject has received rituximab or any immune-cell-depleting therapy within 6 months prior to baseline (Day 1).
- - Subject has received any marketed or investigational biological agent, other than those specified in other inclusion/exclusion criteria, within 12 weeks or 5 half-lives prior to baseline (Day 1).
- - Subject is currently receiving a non-biological investigational product or device or has received one within 4 weeks prior to baseline (Day 1).
- - Subject has received apremilast or other non-biologic systemic treatment for PsA within 4 weeks prior to baseline (Day 1), other than methotrexate (MTX), sulfasalazine, corticosteroids, NSAIDs, or paracetamol/acetaminophen, which are allowed at stable doses as described in Inclusion Criterion 7.
- - Subject has received intraarticular injection (including corticosteroids), intramuscular steroids, intralesional steroids, or intravenous steroids within 4 weeks prior to baseline (Day 1).
- - Subject has received high potency opioid analgesics (eg, methadone, hydromorphone, or morphine) within 2 weeks prior to baseline (Day 1).
- - Subject has used any topical medication that could affect PsA or psoriasis (including corticosteroids, retinoids, vitamin D analogues (such as calcipotriol), JAK inhibitors, or tar) within 2 weeks prior to baseline (Day 1).
- - Subject has used any systemic treatment that could affect PsA or psoriasis (including oral retinoids, immunosuppressive/immunomodulating medication, cyclosporine, oral JAK inhibitors, or apremilast) within 4 weeks prior to baseline (Day 1).
- - Subject has received any ultraviolet (UV)-B phototherapy (including tanning beds) or excimer laser within 4 weeks prior to baseline (Day 1).
- - Subject has had psoralen and UV A (PUVA) treatment within 4 weeks prior to baseline (Day 1).
- - Subject has received Chinese traditional medicine within 4 weeks prior to baseline (Day 1) - Subject has received any live-attenuated vaccine, including for COVID-19, within 4 weeks prior to baseline (Day 1) or plans to receive a live-attenuated vaccine during the study and up to 4 weeks or 5 half-lives of the study drug, whichever is longer, after the last study drug administration.
- - Subject is currently being treated with strong or moderate cytochrome P450 3A (CYP3A4) inhibitors, such as itraconazole or has received moderate or strong CYP3A4 inhibitors within 4 weeks prior to baseline (Day 1).
- - Subject has consumed grapefruit or grapefruit juice within 1 week prior to baseline (Day 1).
- - Subject has used tanning booths within 4 weeks prior to baseline (Day 1), has had excessive sun exposure, or is not willing to minimize natural and artificial sunlight exposure during the study.
- - Subject is a female who is breastfeeding, pregnant, or who is planning to become pregnant during the study.
- - Subject has evidence of erythrodermic, pustular, predominantly guttate psoriasis, or drug-induced psoriasis.
- - Subject has a history of skin disease or presence of skin condition that, in the opinion of the investigator, would interfere with the study assessments.
- - Subject has any clinically significant medical condition, evidence of an unstable clinical condition, psychiatric condition, or vital signs/physical/laboratory/ECG abnormality that would, in the opinion of the investigator, put the subject at undue risk or interfere with interpretation of study results.
- - Subject had a major surgery within 8 weeks prior to baseline (Day 1 or has a major surgery planned during the study.
- - Subject has a history of Class III or IV congestive heart failure as defined by New York Heart Association Criteria.
- - Subject has an estimated creatinine clearance of < 40 mL/min based on the Cockcroft-Gault equation or a history of renal failure.
- - Subject was hospitalized in the 3 months prior to screening for asthma, has ever required intubation for treatment of asthma, currently require oral corticosteroids for the treatment of asthma, or has required more than one short-term (≤ 2 weeks) course of oral corticosteroids for asthma within 6 months prior to baseline (Day 1).
- - Subject has a history of cancer or lymphoproliferative disease within 5 years prior to baseline (Day 1).
- - Subject has a history of fever, inflammation, or systemic signs of illness suggestive of systemic or invasive infection within 4 weeks prior to baseline (Day 1).
- - Subject has an active bacterial, viral, fungal, mycobacterial infection, or other infection (including TB or atypical mycobacterial disease), or any major episode of infection that required hospitalization or treatment with intravenous antibiotics within 12 weeks prior to baseline (Day 1), or oral antibiotics within 4 weeks prior to baseline (Day 1).
- - Subject has a history of chronic or recurrent infectious disease, including but not limited to chronic renal infection, chronic chest infection, recurrent urinary tract infection, fungal infection (with the exception of superficial fungal infection of the nailbed), or infected skin wounds or ulcers.
- - Subject has a history of an infected joint prosthesis or has received antibiotics for a suspected infection of a joint prosthesis, if that prosthesis has not been removed or replaced.
- - Subject has active herpes infection, including herpes simplex 1 and 2 and herpes zoster within 8 weeks prior to Day 1.
- - Subject has a history of known or suspected congenital or acquired immunodeficiency state or condition that would compromise the subject's immune status (eg, history of splenectomy, primary immunodeficiency).
- - Subject has positive results for hepatitis B surface antigens (HBsAg), antibodies to hepatitis B core antigens (anti-HBc), hepatitis C virus (HCV), or human immunodeficiency virus (HIV).
- - Subject has clinical or laboratory evidence of active or latent TB infection at screening as assessed by QuantiFERON-TB Gold (or a purified protein derivative [PPD] skin test or equivalent, or both if required per local guidelines) and chest X-ray.
- - Subject has a known or suspected allergy to NDI-034858 or any component of the investigational product, or any other significant drug allergy (such as anaphylaxis or hepatotoxicity).
- - Subject has a known history of clinically significant drug or alcohol abuse in the last year prior to baseline (Day 1).
Trial Details
Trial ID:
This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries. |
NCT05153148 |
Phase
Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans. Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data. Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use. |
Phase 2 |
Lead Sponsor
The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data. |
Nimbus Lakshmi, Inc. |
Principal Investigator
The person who is responsible for the scientific and technical direction of the entire clinical study. |
Esha Gangolli, PhD |
Principal Investigator Affiliation | Nimbus Lakshmi, Inc. |
Agency Class
Category of organization(s) involved as sponsor (and collaborator) supporting the trial. |
Industry |
Overall Status | Recruiting |
Countries | Bulgaria, Czechia, Germany, Poland, United States |
Conditions
The disease, disorder, syndrome, illness, or injury that is being studied. |
Psoriatic Arthritis |
This is a Phase 2b, Randomized, Multi-center, Double-Blind, Placebo-Controlled, Multiple Dose Study . Randomization to one of the treatments with NDI-034858 Dose 1, 2, 3 or placebo once daily (QD) will be based on a 1:1:1:1 scheme. The maximum study duration per subject is approximately 20 weeks, including up to 30 days for the screening period, a 12-week treatment period, and a 4-week safety follow-up period. Efficacy will be assessed using the ACR20 composite measure (including tender and swollen joint count, patient assessment of PsA pain visual analog scale (VAS), patient global PsA assessment VAS, physician global PsA assessment, HAQ-DI, and hsCRP) as well as the additional components. Efficacy for psoriasis among subjects who have ≥ 3% BSA) involvement on Day 1, will be measured using PASI, PGAs, and BSA. Safety will be assessed by collecting AEs, recording vital signs, performing physical examinations, and evaluating clinical laboratory and ECGs results.
Arms
Experimental: NDI-034858 study drug - Dose 1
NDI-034858 study drug will be orally administered QD for 12 weeks
Experimental: NDI-034858 study drug - Dose 2
NDI-034858 study drug will be orally administered QD for 12 weeks
Experimental: NDI-034858 study drug - Dose 3
NDI-034858 study drug will be orally administered QD for 12 weeks
Placebo Comparator: Placebo
Placebo will be orally administered QD for 12 weeks
Interventions
Drug: - NDI-034858
Randomized participants will receive NDI-034858 capsule orally
Other: - Placebo
Randomized participants will receive placebo orally
Contact a Trial Team
If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.
Status
Recruiting
Address
Nimbus site #XYZ
Palm Desert, California, 92260-9368
Status
Not yet recruiting
Address
Nimbus site #XYZ
Temecula, California, 92592
Status
Recruiting
Address
Nimbus site #XYZ
Upland, California, 91786
Status
Recruiting
Address
Nimbus site #XYZ
Hollywood, Florida, 33024
Status
Recruiting
Address
Nimbus site #XYZ
Plantation, Florida, 33324
Status
Recruiting
Address
Nimbus site #XYZ
Saint Petersburg, Florida, 33705
Status
Recruiting
Address
Nimbus site #XYZ
Tampa, Florida, 33613
Status
Recruiting
Address
Nimbus site #XYZ
Tampa, Florida, 33614
Status
Recruiting
Address
Nimbus site #XYZ
Winter Park, Florida, 32789
Status
Recruiting
Address
Nimbus site #XYZ
Zephyrhills, Florida, 33542
Status
Not yet recruiting
Address
Nimbus site #XYZ
Indianapolis, Indiana, 46250-2041
Status
Not yet recruiting
Address
Nimbus site #XYZ
West Des Moines, Iowa, 50265
Status
Not yet recruiting
Address
Nimbus site #XYZ
Louisville, Kentucky, 40217
Status
Recruiting
Address
Nimbus site #XYZ
Lake Charles, Louisiana, 70605
Status
Recruiting
Address
Nimbus site #XYZ
Worcester, Massachusetts, 01605
Status
Recruiting
Address
Nimbus site #XYZ
Albuquerque, New Mexico, 87102
Status
Recruiting
Address
Nimbus site #XYZ
Charlotte, North Carolina, 28210
Status
Not yet recruiting
Address
Nimbus site #XYZ
Salisbury, North Carolina, 28144
Status
Not yet recruiting
Address
Nimbus site #XYZ
Wilmington, North Carolina, 28401-6442
Status
Recruiting
Address
Nimbus site #XYZ
Duncansville, Pennsylvania, 16635
Status
Not yet recruiting
Address
Nimbus site #XYZ
Columbia, South Carolina, 29204
Status
Recruiting
Address
Nimbus site #XYZ
Jackson, Tennessee, 38305
Status
Recruiting
Address
Nimbus site #XYZ
Baytown, Texas, 77521
Status
Not yet recruiting
Address
Nimbus site #XYZ
Colleyville, Texas, 76034
Status
Recruiting
Address
Nimbus site #XYZ
Corpus Christi, Texas, 78404
Status
Recruiting
Address
Nimbus site #XYZ
Houston, Texas, 77089
Status
Recruiting
Address
Nimbus site #XYZ
Mesquite, Texas, 75150
Status
Recruiting
Address
Nimbus site #XYZ
Beckley, West Virginia, 25801
International Sites
Status
Not yet recruiting
Address
Nimbus site #XYZ
Pleven, , 5803
Status
Not yet recruiting
Address
Nimbus site #XYZ
Sofia, , 1431
Status
Not yet recruiting
Address
Nimbus site #XYZ
Sofia, , 1612
Status
Not yet recruiting
Address
Nimbus site #XYZ
Sofia, , 1784
Status
Recruiting
Address
Nimbus site #XYZ
Hlučín, Ostrava-město, 748 01
Status
Recruiting
Address
Nimbus site #XYZ
Praha, Praha 3, 130 00
Status
Recruiting
Address
Nimbus site #XYZ
Ostrava, , 702 00
Status
Recruiting
Address
Nimbus site #XYZ
Pardubice, , 530 02
Status
Not yet recruiting
Address
Nimbus site #XYZ
Uherské Hradiště, , 686 01
Status
Recruiting
Address
Nimbus site #XYZ
Zlin, , 760 01
Status
Not yet recruiting
Address
Nimbus site #XYZ
Cottbus, Brandenburg, 03042
Status
Not yet recruiting
Address
Nimbus site #XYZ
Frankfurt, Hessen, 60590
Status
Not yet recruiting
Address
Nimbus site #XYZ
Bonn, Nordrhein-Westfalen, 53127
Status
Not yet recruiting
Address
Nimbus site #XYZ
Cologne, Nordrhein-Westfalen, 50937
Status
Not yet recruiting
Address
Nimbus site #XYZ
Herne, Nordrhein-Westfalen, 44649
Status
Not yet recruiting
Address
Nimbus site #XYZ
Ratingen, Nordrhein-Westfalen, 40878
Status
Not yet recruiting
Address
Nimbus site #XYZ
Berlin, , 12161
Status
Not yet recruiting
Address
Nimbus site #XYZ
Berlin, , 14059
Status
Not yet recruiting
Address
Nimbus site #XYZ
Hamburg, , 20095
Status
Not yet recruiting
Address
Nimbus site #XYZ
Hamburg, , 22415
Status
Not yet recruiting
Address
Nimbus site #XYZ
Lublin, Lubelskie, 20-607
Status
Recruiting
Address
Nimbus site #XYZ
Kraków, Malopolskie, 30-033
Status
Not yet recruiting
Address
Nimbus site #XYZ
Elblag, Warminsko-mazurskie, 82-300
Status
Not yet recruiting
Address
Nimbus site #XYZ
Bialystok, , 15-077
Status
Not yet recruiting
Address
Nimbus site #XYZ
Bydgoszcz, , 85-065
Status
Recruiting
Address
Nimbus site #XYZ
Krakow, , 30-363
Status
Recruiting
Address
Nimbus site #XYZ
Kraków, , 30-149
Status
Recruiting
Address
Nimbus site #XYZ
Nadarzyn, , 05-830
Status
Recruiting
Address
Nimbus site #XYZ
Nowa Sol, , 67-100
Status
Recruiting
Address
Nimbus site #XYZ
Poznan, , 60-218
Status
Recruiting
Address
Nimbus site #XYZ
Poznan, , 61-293
Status
Recruiting
Address
Nimbus site #XYZ
Poznań, , 61-397
Status
Not yet recruiting
Address
Nimbus site #XYZ
Poznań, , 61-731
Status
Recruiting
Address
Nimbus site #XYZ
Sochaczew, , 96-500
Status
Not yet recruiting
Address
Nimbus site #XYZ
Torun, , 87-100
Status
Recruiting
Address
Nimbus site #XYZ
Warszawa, , 02-665
Status
Recruiting
Address
Nimbus site #XYZ
Wroclaw, , 50-244
Status
Recruiting
Address
Nimbus site #XYZ
Wroclaw, , 51-318